Ruxolitinib for Adult T-Cell Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ruxolitinib
Related studies linked through entity extraction aliases.
Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
- Status
- COMPLETED
- Phase
- PHASE1
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
- Status
- COMPLETED
- Phase
- PHASE3
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib in Patients With Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE2
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE1
Study of Ruxolitinib in Pancreatic Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
- Status
- COMPLETED
- Phase
- PHASE2
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
- Status
- COMPLETED
- Phase
- PHASE1
Phase l/II Study of Ruxolitinib for Acute Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
- Status
- COMPLETED
- Phase
- PHASE3
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
- Status
- COMPLETED
- Phase
- PHASE3